Auranofin therapy for juvenile rheumatoid arthritis: results of the five-year open label extension trial.

Eighty-eight children with juvenile rheumatoid arthritis (JRA) who completed a double blind, randomized placebo controlled trial of oral gold were entered into an open label extension phase during which they received auranofin (AF) at a dosage of 0.15-0.2 mg/kg/day (9 mg/day maximum). Eleven (12.5%) patients completed 5 years of AF therapy; 77 (87.5%) did not. Fifteen (17%) of the 88 were in disease remission at the final visit. Mean duration of therapy for those who discontinued was 646 days. Parental/patient decision and insufficient therapeutic effect were the 2 most frequent reasons for early termination, followed by adverse effects. Though relatively well tolerated, AF provides adequate longterm management for only a small percentage of patients with JRA.

88名幼年类风湿性关节炎（JRA）患儿完成了一项口服金制剂的双盲、随机、安慰剂对照试验后，进入开放标签扩展阶段，在此期间他们接受金诺芬（AF）治疗，剂量为0.15 - 0.2毫克/千克/天（最大9毫克/天）。11名（12.5%）患者完成了5年的AF治疗；77名（87.5%）未完成。88名患者中有15名（17%）在最后一次就诊时病情缓解。停药患者的平均治疗时长为646天。家长/患者决定和治疗效果不佳是提前终止治疗的两个最常见原因，其次是不良反应。尽管耐受性相对较好，但金诺芬仅对一小部分JRA患者提供了足够的长期治疗。